Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1306)	9/29/1998 12:50:00 PM
From: yosi s	Read Replies (1) \| Respond to of 1491

is the delay in news release an effort to keep news focus on the company. I think not. It probably reflects conservative scientific thinking that feels that scientific meeting is the place to release such news. This keeps us shareholder on hold, yet we will go to phase 3, so how good are the results.

To: Ariella who wrote (1306)	10/5/1998 8:27:00 AM
From: David Israel-Rosen	Read Replies (1) \| Respond to of 1491

Good Morning Ariellla: Monday October 5, 7:45 am Eastern Time Company Press Release SOURCE: Pharmos Corporation Experimental Treatment for Severe Head Trauma Pharmos Corporation will announce the results of a Phase II clinical trial that evaluated dexanabinol, a marijuana analog, in treating severe head trauma. A teleconference will be held shortly after the announcement. WHO: Dr. Nachshon Knoller, MD, principal investigator DATE: October 7, 1998 TIME: 10:00 a.m. PT If you would like to participate in the teleconference, please call Gwyn Crosson at 732-603-3526 or Lev Janashvili at 212-583-2761 to obtain the dial-in number for the teleconference or call Barbara Peck in the press room at 206-505-6476 to attend in person. Head Trauma Factoid There is currently no approved drug for the treatment of head trauma. Head trauma is the number one cause of death for people aged 18-30. In the U.S. alone, more than 373,000 people are hospitalized for severe head injuries each year, and more than 99,000 of these individuals sustain moderate to severe brain injuries that result in lifelong disabling conditions. SOURCE: Pharmos Corporation